Cabenuva injection is a 2-drug co-packaged product that combines cabotegravir, an HIV integrase strand transfer inhibitor, and rilpivirine, an HIV non-nucleoside reverse transcriptase inhibitor. The ...

Simultaneous approval of VOCABRIA (cabotegravir oral tablets), for short-term treatment in conjunction with CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), also ...

People with HIV may have to take multiple medicines just to keep the virus under control. Medicines for HIV are usually taken every day, and it is crucial that people do not miss their dose or else ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive findings from the ...

Last week, the FDA denied the approval of Cabenuva, the first of its kind monthly HIV injection treatment. Developers hoped that the monthly injection would replace daily pills, thus making life ...

TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S.

(Reuters) - GlaxoSmithKline's HIV treatments division has received approval for its long-acting HIV injection from Canada's healthcare regulator, in a major win for the British drugmaker after a U.S.

A kit with two injectable medicines—ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine— CABENUVA was co-developed as part of a collaboration with Janssen and builds on ViiV Healthcare’s industry ...

You can save this article by registering for free here. Or sign-in if you have an account. GlaxoSmithKline’s HIV treatments division has received approval for its long-acting HIV injection from Canada ...

CABENUVA allows virologically suppressed adults living with HIV to maintain viral suppression while reducing their dosing schedule from 365 days to 12 days per year. VOCABRIA and CABENUVA should not ...

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment Cabenuva allows virologically suppressed adults living ...